Cardiovascular risk factors: Belgian target achievement

References

• Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P. Boysen G, Cifkova R, Deaton C, Ebrahim 5, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S. Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012):The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33:1635–701.
   Google Scholar
• Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981–2000: comparing contributions from primary prevention and secondary prevention. BMJ2005; 331:614.
   Google Scholar
• Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005; 143:659–72.
   Google Scholar
• Taylor RS, Brown A, Ebrahim 5, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA, Thompson DR, Oldridge N. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116: 682–92.
   Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim 5, Faergeman 0, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans 5, Sansoy V. Sechtem U, Silber S. Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prey Rehabil 2003; 10: 51–10.
   Google Scholar
• Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim 5, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries 5, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez 5, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber 5, Tendera M, Widimsky P. Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giam-paoli 5, Hemingway H, Hakansson J, Kjeldsen SE, Larsen mL, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund 0, Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prey Rehabil 2007; 14 Suppl 2: 51–113.
   Google Scholar
• Pyorala K, De Backer G, Graham I, Poole-Wilson P. Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur HeartJ 1994; 15:1300–31.
   Google Scholar
• Wood D, De Backer G, Faergeman 0, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens 1998; 16:1407–14.
   Google Scholar
• Conroy RM, Pyorala K, Fitzgerald AP, Sans 5, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P. Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM. Estimation often-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur HeartJ 2003; 24:987–1003
   Google Scholar
• De Bacquer D, De Backer G. Predictive ability of the SCORE Belgium risk chart for cardiovascular mortality. Int J Cardiol 2010; 143:385–90.
   Google Scholar
• Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C, Masso-Gonzalez EL, Sazova 0, Perk J, Steg PG, De Backer G, Rodriguez-Artalejo F. Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study. Int J Cardiol 2013; 166:210–4.
   Google Scholar
• Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C, Masso-Gonzalez EL, Jimenez FJ, Perk J, Steg PG, De Backer G, Rod riguez-Artalejo F. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011; 32:2143–52.
   Google Scholar
• Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, De Backer G, Halcox JP, Masso-Gonzalez EL, Perk J, Sazova 0, Steg PG, Artalejo FR. Survey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prey Cardiol 2012; 19:541–50.
   Google Scholar
• Rodriguez-Artalejo F, Guallar E, Borghi C, Dallongeville J, De Backer G, Halcox JP, Hernandez-Vecino R, Jimenez FJ, Masso-Gonzalez EL, Perk J, Steg PG, Banegas JR. Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). BMC Public Health 2010; 10:382.
   Google Scholar
• Guallar E, Banegas JR, Blasco-Colmenares E, Jimenez FJ, Dallongeville J, Halcox JP, Borghi C, Masso-Gonzalez EL, Tafalla M, PerkJ, De Backer G, Steg PG, Rodriguez-Artalejo F. Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe -The EURIKA Study. BMC Public Health 2011; 11: 704.
   Google Scholar
• Hermans MP, Brotons C, Elisaf M, Michel G, Muls E, Nobels F. Optimal type 2 diabetes mel-litus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. Eur J Prey Cardiol 2012; 20:1095–105.
   Google Scholar
• Nobels F, Debacker N, Brotons C, Elisaf M, Hermans MP, Michel G, Muls E. Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus. Cardiovasc Diabetol 2011; 10: 82.
   Google Scholar
• Hermans MP, Elisaf M, Michel G, Muls E, Nobels F, Vandenberghe H, Brotons C. Benchmarking is associated with improved quality of care in type 2 diabetes: the OPTIMISE randomized controlled trial. Diabetes Care, 2013; 36: 3388–95.
   Google Scholar
• Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373:929–40.
   Google Scholar
• Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prey Rehabil 2009; 16: 121–37.
   Google Scholar
• Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Reiner Z, Keil U. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prey Rehabil 2010; 17: 530–40.
   Google Scholar
• Kotseva K, Wood D, De Backer G, De Bacquer D. Use and effects of cardiac rehabilitation in patients with coronary heart disease: results from the EUROASPIRE III survey. Eur J Prey Cardiol 2013; 20:817–26.
   Google Scholar
• Cooney MT, Kotseva K, Dudina A, De Backer G, Wood D, Graham I. Determinants of risk factor control in subjects with coronary heart disease: a report from the EUROASPIRE III investigators. Eur J Prey Cardiol 2013; 20:686–91.
   Google Scholar
• Department of general practice, K.U. Leuven. I ntego-project (2011); Available from: http://www.intego.be [cited March 14, 2013]
   Google Scholar
• Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund 0, Agewall 5, Alegria E, Chapman MJ, Durrington P. Erdine 5, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769–818.
   Google Scholar
• Hermans MP, Muls E, Nobels F, Krzentowski G, Claes N, Debacker N, Matthys A. Evaluating benchmarking to optimize management of Type 2 diabetic patients: The Belgian data of the Optimise study (Abstract 41). Presented at the 7th Metabolic Syndrome, Type II diabetes and Atherosclerosis Congress; May 12–16, 2010; Marrakech, Morocco.
   Google Scholar
• Hermans MP, Muls E, Nobels F, Claes N, Krzentowski G, Debacker N, Matthys A. Evaluating Benchmarking to Optimize Management of Type 2 Diabetic Patients: The Belgian Baseline Data (Abstract 60). Presented at the 6th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress; May 20–24, 2009; Berlin, Germany.
   Google Scholar
• Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the healthcare system. BMJ 1999; 318:182–5.
   Google Scholar
• Van Gaal LF, De Block CE. Does pharmacotherapy have a place in the weight management of patients with type 2 diabetes? In: Barnett AH, ed. Clinical challenges in diabetes. Atlas Medical Publishing Ltd, United Kingdom, 2010:55–72.
   Google Scholar
• Bartholomeeusen 5, Vandenbroucke JP, Truyers C, Buntinx F. Trends in total cholesterol screening and in prescribing lipid-lowering drugs in general practice in the period 1994-2003. BMC Fam Pract 2008; 9:39.
   Google Scholar
• Lawes CM, Vander Hoorn 5, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371:1513–8.
   Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393–403.
   Google Scholar
• Ratner R, Goldberg R, Haffner 5, Marcovina S. Orchard T, Fowler 5, Temprosa M. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005; 28:888–94.
   Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P. Keinanen-Kiukaanniemi 5, Laakso M, Louheranta A, Rastas M, Salminen V. Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343–50.
   Google Scholar
• Nobels F, Debacker N, Scheen AJ. Initiave to promote quality of care and epidemiology of diabetes mellitus. Rev Med Liege 2005; 60: 624–7.
   Google Scholar